Accretion Pharmaceuticals Ltd. Stock Analysis ACCPL.NS

Accretion Pharmaceuticals Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat and currently employs 121 full-time employees. The company went IPO on 2025-05-21. The firm is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.